000			04007nam a2200325 i 4500
999			_c399360 _d399360
001			399360
003			ES-MaUEC
005			20240415171205.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			230314s2023 sz | fo |||| 0|eng d
020			_a9783031141003
024	7		_a10.1007/978-3-031-14100-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS199.5 _b2023 EB
245	0	0	_aTubercular Drug Delivery Systems : _bAdvances in Treatment of Infectious Diseases _cedited by Ranjita Shegokar, Yashwant Pathak
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aGlobal health and Tuberculosis past, present and Future -- Tuberculosis: cellular understanding of disease.-Metal nanoparticles in TB -- TB: current treatment options -- Polymeric nanoparticles in TB -- Solid lipid nanoparticles in TB -- Dendrimers in TB -- Liposomes in TB -- Micro, nano emulsions in TB -- Nano suspension in TB -- Alginate, gelatin nanoparticles in TB -- Niosome in TB -- Surface modified drug delivery systems in TB -- Clinical trials in TB -- Herbal platforms in TB.
520			_aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the microorganisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity. A total of four books are covered under the series of Infectious diseases. • Malarial drug delivery systems • Tubercular drug delivery systems • Viral drug delivery systems • Infectious disease drug delivery systems The theme of the second book is Tuberculosis (TB). This book addresses the recent trends in drug delivery for treating TB using new formulation technologies, and the mechanism how it can prevent or delay the drug resistance. It covers current drug therapy and new drug targeting approaches focusing on innovative trend-defining technologies and drug delivery platforms. It is essential to understand the relationship between host pathogens for better treatment. Various novel and nano-formulations using promising technologies are being explored to deliver TB drugs via different administration routes at right pathological site. This book addresses the gap between new and old treatment TB modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of TB research.
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9667667 _aSistemas de liberación de fármacos
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-14100-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b04/2024 _dq _eb _zSI